PELyon, Lyon, France; HESPER 7425, Health Services and Performance Research, Lyon, France.
PELyon, Lyon, France; HESPER 7425, Health Services and Performance Research, Lyon, France.
J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):877-83. doi: 10.1016/j.jaip.2016.06.012. Epub 2016 Jul 21.
In asthma, choice of controller therapy and adherence to treatment can affect the risk of future severe exacerbations leading to hospitalization.
Our objective was to characterize treatment dispensation profiles before hospital admission for asthma.
Using a 1/97th random sample of the national French claims data, patients with asthma aged 6 to 40 years were identified between 2006 and 2014. Patients with subsequent asthma-related hospitalization were selected. On the basis of controller therapy dispensed in the 12 months before admission, treatment profiles were categorized into clusters, using Ward's minimum-variance hierarchical clustering method.
Of 17,846 patients with asthma, we identified 275 patients (1.5%) with an asthma-related hospitalization. Three distinct clusters were identified. The first cluster (63.6%) included patients with few dispensations of any controller medication (<1 unit). The second cluster (32.4%) consisted of patients with frequent dispensations of long-acting beta agonists (LABAs)/inhaled corticosteroids (ICS) in fixed-dose combinations. The third cluster (4%) comprised patients receiving free combinations of ICS and LABAs, with more dispensations of LABAs than of ICS.
In France, before an asthma-related hospitalization, more than 60% of patients received little controller therapy and 4% were exposed to higher dispensation of LABAs than of ICS. These results indicate that a large fraction of asthma-related hospitalizations can potentially be prevented with better pharmacotherapy.
在哮喘中,控制药物治疗的选择和治疗的依从性会影响未来严重加重导致住院的风险。
我们的目的是描述哮喘入院前的治疗分配情况。
使用全国法国索赔数据的 1/97 随机样本,确定了 2006 年至 2014 年间年龄在 6 至 40 岁之间的哮喘患者。选择随后发生哮喘相关住院的患者。基于入院前 12 个月内开出的控制药物,使用 Ward 的最小方差分层聚类方法将治疗方案分类为聚类。
在 17846 例哮喘患者中,我们确定了 275 例(1.5%)哮喘相关住院患者。确定了三个不同的聚类。第一个聚类(63.6%)包括接受任何控制药物(<1 单位)分配次数较少的患者。第二个聚类(32.4%)由经常分配长效β激动剂(LABA)/吸入皮质激素(ICS)固定剂量组合的患者组成。第三个聚类(4%)包括接受 ICS 和 LABA 自由组合的患者,LABA 的分配次数多于 ICS。
在法国,哮喘相关住院前,超过 60%的患者接受的控制药物治疗较少,4%的患者接受的 LABA 分配次数多于 ICS。这些结果表明,通过更好的药物治疗,可能预防大量哮喘相关住院。